MISSISSAUGA, ONTARIO--(Marketwired - May 7, 2013) - CML HealthCare Inc. (CLC.TO) (the "Company" or "CML"), a leading community-based Canadian provider of diagnostic testing for integrative health is ...
FORT LAUDERDALE, Fla. -- OmniComm Systems, Inc. (OTC:OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that Inflamax Research, a full ...
City-based full service clinical research organisation (CRO) Cliantha Research has acquired US-based Inflamax Research. The deal enables Cliantha Research to conduct Phase I, II, III and IV clinical ...
BioWorld - Tuesday, June 10, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » Inflamax Pharmaceuticals patents new PACE4 ...
Cliantha Research has acquired US-based Inflamax Research, a deal that will enable the Ahmedabad-based company to conduct Phase I, II, III and IV research in North America, the company said in a ...
For CROs running trials around the globe, amassing loads of data is no sweat, but sharing it with sponsors in disparate countries and keeping it all in line for an ...
Cliantha Research has announced acquisition of Inflamax Research which has locations in Toronto and Newark. Cliantha Research will have the capabilities to perform phase I, II, III and IV clinical ...
Inflamax Pharmaceuticals (Guangzhou) Co. Ltd. has disclosed proprotein convertase subtilisin/kexin-type 6 (PCSK6; PACE4; PC7A) inhibitors reported to be useful for the treatment of osteoarthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results